Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral presentations. A mini-oral presentation featured the largest molecular residual disease (MRD) dataset ever presented in lung cancer. This analysis of 1,129 patients with rese.

Business Wire • Sep 18, 2026

This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters.

Instead, it's -- of all things -- a medical diagnostics company. In this niche, the company has several compelling advantages.

The Motley Fool • Sep 14, 2026

Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)

Stanley Druckemiller holds some smaller positions in Amazon and Alphabet. His largest stockholding is a company called Natera, which does DNA diagnostics.

The Motley Fool • Sep 8, 2026

Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

ETF Trends • Sep 2, 2026

New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their performance is limited, with positive predictive value (PPV) reported as low as 50%.

Business Wire • Sep 1, 2026

Natera & Angiex Partner to Evaluate AGX101 Response With Signatera

NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.

Zacks Investment Research • Aug 28, 2026

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including.

Business Wire • Aug 28, 2026

Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and.

Business Wire • Aug 27, 2026

Billionaire Stanley Druckenmiller's Top Holding Is Up 37% This Year. Is the Market Pricing in the Full Story?

Billionaire investor Stanley Druckenmiller holds an $865 million position in Natera. Shares in the diagnostics company have surged over 37% year to date.

The Motley Fool • Aug 20, 2026

Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.

Zacks Investment Research • Aug 17, 2026